Papi C, Ciaco A, Koch M, Capurso L
Department of Digestive Diseases & Nutrition, Ospedale S. Filippo Neri, Rome, Italy.
Aliment Pharmacol Ther. 1995 Feb;9(1):33-9. doi: 10.1111/j.1365-2036.1995.tb00348.x.
In a recent open trial we have shown the efficacy of long term intermittent administration of a poorly absorbable antibiotic (rifaximin) in obtaining symptomatic relief in uncomplicated diverticular disease of the colon. The aim of this double-blind placebo-controlled trial was to test our previous observations.
One hundred and sixty-eight outpatients with symptomatic uncomplicated diverticular disease were treated with fibre supplementation (glucomannan 2 g/day) plus rifaximin 400 mg b.d. for 7 days every month (84 patients), or with glucomannan 2 g/day plus placebo two tablets b.d. for 7 days every month (84 patients). Clinical evaluation was performed at admission and at three-month intervals for 12 months.
After 12 months, 68.9% of the patients treated with rifaximin were symptom-free or mildly symptomatic, compared to 39.5% in the placebo group (P = 0.001). Symptoms such as bloating and abdominal pain or discomfort were primarily affected by antibiotic treatment when compared with placebo (P < 0.001).
Rifaximin appears to be of some advantage in obtaining symptomatic relief in diverticular disease of the colon when compared with fibre supplementation alone.
在最近的一项开放试验中，我们已证明长期间歇性给予一种难吸收抗生素（利福昔明）对缓解单纯性结肠憩室病的症状有效。这项双盲安慰剂对照试验的目的是验证我们之前的观察结果。
168例有症状的单纯性憩室病门诊患者接受了纤维补充剂（葡甘露聚糖2克/天）加利福昔明400毫克每日两次，每月服用7天（84例患者），或葡甘露聚糖2克/天加安慰剂两片每日两次，每月服用7天（84例患者）。在入院时以及之后的12个月中每三个月进行一次临床评估。
12个月后，接受利福昔明治疗的患者中有68.9%无症状或症状轻微, 而安慰剂组为39.5%（P = 0.001）。与安慰剂相比，腹胀、腹痛或不适等症状主要受到抗生素治疗的影响（P < 0.001）。
与单独补充纤维相比，利福昔明在缓解结肠憩室病症状方面似乎具有一定优势。
